Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$5.35 +2.3%	$6.12	$4.84 ▼ $12.38	$268.70M	0.43	205,819 shs	170,796 shs
DBVT DBV Technologies	$10.13 +3.1%	$6.91	$2.20 ▼ $11.09	$277.46M	-0.66	186,250 shs	150,471 shs
TARS Tarsus Pharmaceuticals	$44.20 -1.3%	$48.26	$20.08 ▼ $57.28	$1.86B	0.94	690,144 shs	885,000 shs
VYGR Voyager Therapeutics	$3.35 +5.7%	$3.50	$2.75 ▼ $9.55	$185.30M	0.95	446,728 shs	662,542 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	-14.96%	-1.32%	-32.60%	-28.45%
DBVT DBV Technologies	0.00%	+9.83%	+34.29%	+134.05%	+70.66%
TARS Tarsus Pharmaceuticals	0.00%	-5.26%	-3.36%	-13.31%	+21.27%
VYGR Voyager Therapeutics	0.00%	-10.99%	+2.21%	-39.10%	-61.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	2.2997 of 5 stars	3.6	2.0	0.0	2.7	2.5	0.0
DBVT DBV Technologies	3.2981 of 5 stars	3.5	5.0	0.0	3.3	1.7	0.6
TARS Tarsus Pharmaceuticals	3.0292 of 5 stars	4.5	0.0	0.0	3.4	2.5	0.6
VYGR Voyager Therapeutics	4.6763 of 5 stars	4.6	1.0	4.6	2.5	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.25	Buy	$22.75	325.23% Upside
DBVT DBV Technologies	3.00	Buy	$15.50	53.01% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.33	50.08% Upside
VYGR Voyager Therapeutics	3.11	Buy	$13.97	316.90% Upside

Current Analyst Ratings Breakdown

Latest TARS, AURA, VYGR, and DBVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/5/2025	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$46.00 ➝ $51.00
5/2/2025	TARS Tarsus Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $84.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00
4/8/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/26/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$19.00
3/26/2025	AURA Aura Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/25/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$25.00
3/24/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/13/2025	VYGR Voyager Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
3/13/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$4.58 per share	N/A
DBVT DBV Technologies	$15.73M	17.64	N/A	N/A	$7.27 per share	1.39
TARS Tarsus Pharmaceuticals	$233.67M	7.95	N/A	N/A	$5.95 per share	7.43
VYGR Voyager Therapeutics	$80.00M	2.32	$2.38 per share	1.41	$5.37 per share	0.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$76.41M	-$1.75	N/A	N/A	N/A	N/A	-41.57%	-36.43%	N/A
DBVT DBV Technologies	-$72.73M	-$4.92	N/A	N/A	N/A	-815.73%	-106.07%	-76.17%	7/29/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$135.89M	-$2.73	N/A	N/A	N/A	-103.64%	-55.86%	-39.28%	5/14/2025 (Estimated)
VYGR Voyager Therapeutics	$132.33M	-$1.46	4.72	N/A	N/A	15.80%	8.33%	6.15%	5/12/2025 (Estimated)

Latest TARS, AURA, VYGR, and DBVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.75	N/A	N/A	N/A	$71.19 million	N/A
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A
3/11/2025	Q4 2024	VYGR Voyager Therapeutics	-$0.35	-$0.59	-$0.24	-$0.59	$16.58 million	$4.39 million
2/25/2025	Q4 2024	TARS Tarsus Pharmaceuticals	-$0.68	-$0.60	+$0.08	-$0.60	$58.80 million	$66.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	12.47	12.47
DBVT DBV Technologies	N/A	2.22	2.22
TARS Tarsus Pharmaceuticals	0.30	5.42	5.38
VYGR Voyager Therapeutics	N/A	8.45	8.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
DBVT DBV Technologies	71.74%
TARS Tarsus Pharmaceuticals	90.01%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	5.40%
DBVT DBV Technologies	1.90%
TARS Tarsus Pharmaceuticals	8.25%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	50.23 million	47.25 million	Not Optionable
DBVT DBV Technologies	80	27.39 million	20.18 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	35.07 million	Optionable
VYGR Voyager Therapeutics	100	55.31 million	52.15 million	Optionable

TARS, AURA, VYGR, and DBVT Headlines

Recent News About These Companies

What is Leerink Partnrs' Forecast for VYGR Q2 Earnings?

May 11 at 8:11 AM | marketbeat.com

Wedbush Equities Analysts Boost Earnings Estimates for VYGR

May 11 at 8:11 AM | marketbeat.com

Farallon Capital Management LLC Has $14.58 Million Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

May 11 at 7:40 AM | marketbeat.com

FY2025 EPS Estimates for VYGR Raised by Cantor Fitzgerald

May 11 at 2:17 AM | americanbankingnews.com

Q2 Earnings Estimate for VYGR Issued By Leerink Partnrs

May 11 at 1:09 AM | americanbankingnews.com

Wedbush Issues Optimistic Forecast for VYGR Earnings

May 11 at 1:09 AM | americanbankingnews.com

What is Leerink Partnrs' Forecast for VYGR FY2029 Earnings?

May 10 at 9:30 AM | marketbeat.com

Voyager Therapeutics, Inc.: Voyager Reports First Quarter 2025 Financial and Operating Results

May 9 at 10:49 PM | finanznachrichten.de

Analysts Set Expectations for VYGR FY2029 Earnings

May 9 at 4:15 AM | americanbankingnews.com

Raymond James Financial Inc. Takes $746,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

May 9 at 3:27 AM | marketbeat.com

Neurocrine hands back 2 CNS gene therapy programs to Voyager

May 7, 2025 | fiercebiotech.com

Voyager Therapeutics (VYGR) Expected to Announce Quarterly Earnings on Monday

May 7, 2025 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates

May 6, 2025 | zacks.com

Voyager Reports First Quarter 2025 Financial and Operating Results

May 6, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Renaissance Technologies LLC

May 4, 2025 | marketbeat.com

Institutional Shifts at Voyager Therapeutics Reflect Trends in NASDAQ Companies by Market Cap

May 2, 2025 | kalkinemedia.com

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

April 28, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Buy" from Brokerages

April 22, 2025 | marketbeat.com

Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...

April 21, 2025 | finance.yahoo.com

FY2026 Earnings Forecast for VYGR Issued By Leerink Partnrs

April 20, 2025 | marketbeat.com

7 Analysts Assess Voyager Therapeutics: What You Need To Know

April 10, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS, AURA, VYGR, and DBVT Company Descriptions

Aura Biosciences NASDAQ:AURA

$5.35 +0.12 (+2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$5.34 0.00 (-0.09%)

As of 04:21 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

DBV Technologies NASDAQ:DBVT

$10.13 +0.30 (+3.05%)

Closing price 04:00 PM Eastern

Extended Trading

$10.11 -0.02 (-0.20%)

As of 06:54 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Tarsus Pharmaceuticals NASDAQ:TARS

$44.20 -0.56 (-1.25%)

Closing price 04:00 PM Eastern

Extended Trading

$45.14 +0.94 (+2.14%)

As of 07:56 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Voyager Therapeutics NASDAQ:VYGR

$3.35 +0.18 (+5.68%)

Closing price 04:00 PM Eastern

Extended Trading

$3.41 +0.06 (+1.79%)

As of 07:05 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time